{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743719",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743719_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"St John's Wort\" outputclass=\"int-drug\">St John's Wort</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  St John's Wort  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's Wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743720",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743720_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"almotriptan\" outputclass=\"int-drug\">almotriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  almotriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Almotriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743721",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743721_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"bupropion\" outputclass=\"int-drug\">bupropion</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  bupropion  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bupropion</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743722",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743722_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"buspirone\" outputclass=\"int-drug\">buspirone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  buspirone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Buspirone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743723",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743723_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"citalopram\" outputclass=\"int-drug\">citalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  citalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Citalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743724",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743724_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"clomipramine\" outputclass=\"int-drug\">clomipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  clomipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Clomipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743725",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743725_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"dapoxetine\" outputclass=\"int-drug\">dapoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  dapoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dapoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743726",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743726_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"dexamfetamine\" outputclass=\"int-drug\">dexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  dexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743727",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743727_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"duloxetine\" outputclass=\"int-drug\">duloxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  duloxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Duloxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743728",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743728_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"eletriptan\" outputclass=\"int-drug\">eletriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  eletriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Eletriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743729",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743729_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">Naratriptan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the risk of vasoconstriction when given with</ph> <ph otherprops=\"ergotamine\" outputclass=\"int-drug\">ergotamine</ph>. <ph outputclass=\"int-action\">Manufacturer advises separate administration by 24 hours</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Naratriptan   is predicted to   increase   the risk of vasoconstriction when given with   ergotamine .  Manufacturer advises separate administration by 24 hours .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ergotamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743730",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743730_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"escitalopram\" outputclass=\"int-drug\">escitalopram</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  escitalopram  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Escitalopram</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743731",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743731_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"fentanyl\" outputclass=\"int-drug\">fentanyl</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  fentanyl  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fentanyl</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743732",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743732_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"fluoxetine\" outputclass=\"int-drug\">fluoxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  fluoxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluoxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743733",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743733_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"fluvoxamine\" outputclass=\"int-drug\">fluvoxamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  fluvoxamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fluvoxamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743734",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743734_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"frovatriptan\" outputclass=\"int-drug\">frovatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  frovatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Frovatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743735",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743735_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"granisetron\" outputclass=\"int-drug\">granisetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  granisetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Granisetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743736",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743736_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"imipramine\" outputclass=\"int-drug\">imipramine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  imipramine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imipramine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743737",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743737_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"isocarboxazid\" outputclass=\"int-drug\">isocarboxazid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  isocarboxazid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Isocarboxazid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743738",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743738_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"linezolid\" outputclass=\"int-drug\">linezolid</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  linezolid  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Linezolid</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743739",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743739_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"lisdexamfetamine\" outputclass=\"int-drug\">lisdexamfetamine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  lisdexamfetamine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lisdexamfetamine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743740",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743740_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"lithium\" outputclass=\"int-drug\">lithium</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  lithium  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Lithium</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743741",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743741_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"methadone\" outputclass=\"int-drug\">methadone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  methadone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methadone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743742",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743742_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"methylthioninium chloride\" outputclass=\"int-drug\">methylthioninium chloride</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  methylthioninium chloride  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Methylthioninium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743743",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743743_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"mianserin\" outputclass=\"int-drug\">mianserin</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  mianserin  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mianserin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743744",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743744_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"mirtazapine\" outputclass=\"int-drug\">mirtazapine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  mirtazapine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mirtazapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743745",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743745_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"moclobemide\" outputclass=\"int-drug\">moclobemide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  moclobemide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Moclobemide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743746",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743746_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"ondansetron\" outputclass=\"int-drug\">ondansetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  ondansetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ondansetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743747",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743747_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"palonosetron\" outputclass=\"int-drug\">palonosetron</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  palonosetron  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Palonosetron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743748",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743748_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"paroxetine\" outputclass=\"int-drug\">paroxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  paroxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Paroxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743749",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743749_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"pentazocine\" outputclass=\"int-drug\">pentazocine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  pentazocine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pentazocine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743750",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743750_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"pethidine\" outputclass=\"int-drug\">pethidine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  pethidine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pethidine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743751",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743751_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"phenelzine\" outputclass=\"int-drug\">phenelzine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  phenelzine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "33",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenelzine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743752",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743752_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"procarbazine\" outputclass=\"int-drug\">procarbazine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  procarbazine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "34",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Procarbazine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743753",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743753_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"rasagiline\" outputclass=\"int-drug\">rasagiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  rasagiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "35",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rasagiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743754",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743754_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"rizatriptan\" outputclass=\"int-drug\">rizatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  rizatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "36",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rizatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743755",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743755_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"safinamide\" outputclass=\"int-drug\">safinamide</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  safinamide  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "37",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Safinamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743756",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743756_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"selegiline\" outputclass=\"int-drug\">selegiline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  selegiline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "38",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Selegiline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743757",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743757_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"sertraline\" outputclass=\"int-drug\">sertraline</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  sertraline  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "39",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sertraline</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743758",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743758_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"sumatriptan\" outputclass=\"int-drug\">sumatriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  sumatriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "40",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sumatriptan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743759",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743759_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"tapentadol\" outputclass=\"int-drug\">tapentadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  tapentadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "41",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tapentadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743760",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743760_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"tramadol\" outputclass=\"int-drug\">tramadol</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  tramadol  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "42",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tramadol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743761",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743761_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"tranylcypromine\" outputclass=\"int-drug\">tranylcypromine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  tranylcypromine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "43",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tranylcypromine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743762",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743762_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"trazodone\" outputclass=\"int-drug\">trazodone</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  trazodone  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "44",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Trazodone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743763",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743763_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"tryptophan\" outputclass=\"int-drug\">tryptophan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  tryptophan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "45",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tryptophan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743764",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743764_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"venlafaxine\" outputclass=\"int-drug\">venlafaxine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  venlafaxine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "46",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Venlafaxine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743765",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743765_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"vortioxetine\" outputclass=\"int-drug\">vortioxetine</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  vortioxetine  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "47",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Vortioxetine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743766",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2#bnf_i1557280743766_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Normal\" outputclass=\"int-message\">Both <ph otherprops=\"naratriptan\" outputclass=\"int-heading-drug\">naratriptan</ph> and <ph otherprops=\"zolmitriptan\" outputclass=\"int-drug\">zolmitriptan</ph> can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under <xref format=\"dita\" href=\"treatment-summary/antidepressant-drugs.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP78258\">Antidepressant drugs</xref> for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs.</p>"
							},
							"hasEvidence": "NotSet",
							"hasImportance": "NotSet",
							"hasOrder": "1",
							"hasTextContent": "Both  naratriptan  and  zolmitriptan  can increase the risk of serotonin syndrome. See 'Serotonin syndrome' and 'Monoamine-oxidase inhibitor' under  Antidepressant drugs  for more information and for specific advice on avoiding monoamine-oxidase inhibitors during and after administration of other serotonergic drugs. \n\n"
						}
					],
					"hasOrder": "48",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Zolmitriptan</title>"
					}
				}
			],
			"hasSearchLabel": " Naratriptan  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/naratriptan-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Naratriptan </title>"
			},
			"rdfs:label": "naratriptan"
		}
	]
}